NEW YORK, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Marex Group plc ("Marex Group plc" or the "Company") (NASDAQ: MRX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Marex Group plc investors who were adversely affected by alleged securities fraud between May 16, 2024 and August 5, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/marex-group-plc-l ...

Core Viewpoint - MoonLake Immunotherapeutics has been sued for securities fraud, with allegations that the company misrepresented its clinical data and the efficacy of its investigational drug sonelokimab [1][3][4]. Group 1: Lawsuit Details - A lawsuit has been filed against MoonLake and certain senior executives for potential violations of federal securities laws, specifically under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [1][3]. - Investors have until December 15, 2025, to request to be appointed to lead the case, which is pending in the U.S. District Court for the Southern District of New York [3]. Group 2: Company Background - MoonLake is a clinical-stage biotechnology company focused on developing therapies for inflammatory diseases, particularly through its Phase 3 VELA trials for sonelokimab [4]. - The company claimed that its "strong clinical data" from the Phase 2 MIRA trial indicated a superior clinical response for patients compared to competitors [5]. Group 3: Allegations and Impact - The lawsuit alleges that the clinical data and Nanobody structure of sonelokimab did not provide a superior clinical benefit over competitors, raising doubts about the drug's regulatory approval and commercial viability [6]. - Following the announcement of disappointing results from the VELA Phase 3 trials, MoonLake's stock price plummeted nearly 90%, from $61.99 per share to $6.24 per share [7].

Important Notice to Long-Term Shareholders of Maison Solutions Inc. (MSS): Securities Fraud Class Action Approaches Settlement and Grabar Law Investigates Claims on Your BehalfNovember 13, 2025 8:11 AM EST | Source: Grabar Law OfficePhiladelphia, Pennsylvania--(Newsfile Corp. - November 13, 2025) - Grabar Law Office is investigating claims on behalf of shareholders of Maison Solutions Inc. (NASDAQ: MSS) as an underlying securities fraud class action has survived a motion to dismiss the complai ...

Accessibility StatementSkip Navigation PHILADELPHIA , Nov. 12, 2025 /PRNewswire/ -- Kaskela Law LLC announces that it is investigating Priority Technology Holdings, Inc. (NASDAQ: PRTH) ("Priority") on behalf of the company's long-term shareholders. Since February 2025, shares of Priority's common stock have declined in value from over $12.00 per share to a current trading price of less than $6.00 per share – a cumulative decline of over 50% in value. The investigation seeks to determine whether Priority a ...

Core Viewpoint - A class action securities lawsuit has been filed against RCI Hospitality Holdings, Inc. alleging securities fraud affecting investors between December 15, 2021, and September 16, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that the defendants engaged in tax fraud and bribery to conceal this fraud, leading to an understatement of the legal risks faced by the company [3]. - It is alleged that the defendants' statements regarding the company's business, operations, and prospects were materially false and misleading [3]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until November 20, 2025, to request to be appointed as lead plaintiff, although participation does not require serving in this role [4]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [4]. Group 3: Legal Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [5].

Core Viewpoint - Marex Group plc is facing a class action securities lawsuit due to alleged securities fraud that occurred between May 16, 2024, and August 5, 2025, which has adversely affected investors [1][2] Group 1: Lawsuit Details - The lawsuit claims that the defendants made false statements and concealed information regarding the improper inflation of cash flow, revenues, assets, and profits in the Market Making segment through off-book intercompany transactions [2] - As a result of these actions, the positive statements made by the defendants about the Company's business and prospects were materially false and misleading [2] Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until December 8, 2025, to request to be appointed as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees [3] Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record, having secured hundreds of millions of dollars for shareholders and being recognized as one of the top securities litigation firms in the United States for seven consecutive years [4]

Core Viewpoint - A class action securities lawsuit has been filed against James Hardie Industries plc, alleging securities fraud that negatively impacted investors between May 20, 2025, and August 18, 2025 [2][3]. Group 1: Lawsuit Details - The lawsuit aims to recover losses for investors affected by alleged securities fraud during the specified period [2]. - The complaint claims that the defendants made false statements and concealed adverse facts regarding the North America segment of James Hardie, including deteriorating consumer demand and excessive inventory at distributors [3]. Group 2: Investor Information - Investors who suffered losses during the relevant timeframe have until December 23, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [4]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [4]. Group 3: Legal Representation - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [5].

Core Points - A class action securities lawsuit has been filed against DexCom, Inc. to recover losses for shareholders affected by alleged securities fraud between July 26, 2024, and September 17, 2025 [2] - The lawsuit alleges that DexCom made unauthorized material design changes to its glucose monitoring products, the G6 and G7, which rendered them less reliable and posed health risks to users [3] Company Details - The complaint claims that the defendants overstated the enhancements and reliability of the G7 device, downplayed the severity of issues with the G7, and subjected DexCom to increased regulatory scrutiny and potential legal repercussions [3] - The lawsuit indicates that the public statements made by the defendants were materially false and misleading throughout the relevant time period [3] Next Steps - Shareholders who suffered losses in DexCom, Inc. stock during the specified timeframe are encouraged to seek information about their rights to recovery, with no cost or obligation to participate [4] Legal Representation - Levi & Korsinsky LLP, a recognized securities litigation firm, has a history of securing significant recoveries for shareholders and has been ranked among the top securities litigation firms in the United States [5]

Core Viewpoint - A class action lawsuit has been filed against Synopsys, Inc. and certain senior executives for securities fraud following a significant stock drop due to potential violations of federal securities laws [1]. Company Overview - Synopsys, Inc. provides design automation software products used for designing and testing integrated circuits. Its Design IP segment, which supplies pre-designed silicon components to semiconductor companies, has been the fastest-growing segment, increasing from 25% of revenue in 2022 to 31% in 2024 [4]. Allegations and Financial Performance - The lawsuit claims that Synopsys misled investors by stating that customers relied on its IP to minimize integration risk and that the company was experiencing strength in Europe and South Korea. However, it is alleged that customers began requiring more customization for IP components, negatively impacting the economics of the Design IP business and jeopardizing the business model [5]. - In Q3 2025, Synopsys reported a revenue of $425.9 million for its Design IP segment, reflecting a 7.7% year-over-year decline, and a net income of $242.5 million, which is a 43% year-over-year decline. The company indicated that increased customization demands from customers were prolonging processes and requiring more resources [6]. Stock Market Reaction - Following the release of disappointing Q3 2025 financial results, Synopsys's stock price fell from $604.37 per share on September 9, 2025, to $387.78 per share on September 10, 2025, marking a nearly 36% decline [6].

Core Viewpoint - Avantor, Inc. is facing a securities fraud class action lawsuit due to significant stock price declines following disappointing financial results and management changes, with a deadline for investors to file a lead plaintiff motion by December 29, 2025 [1][15]. Financial Performance - On April 25, 2025, Avantor reported first quarter results that missed consensus estimates and reduced guidance for the remainder of 2025, citing increased competitive intensity [2]. - Following this announcement, Avantor's stock price dropped by $2.57, or 16.6%, closing at $12.93 per share [3]. - On August 1, 2025, the company again missed estimates in its second quarter results, revealing a year-over-year decrease in net sales and further reducing its 2025 guidance [3][4]. - This led to a further decline in stock price by $2.08, or 15.5%, closing at $11.36 per share [4]. - On October 29, 2025, Avantor disclosed disappointing third quarter results, including a -5% organic revenue growth and a net loss of $712 million, primarily due to a non-cash goodwill impairment charge of $785 million [5]. - The stock price fell by $3.50, or 23.2%, closing at $11.58 per share following this announcement [6]. Lawsuit Details - The class action lawsuit alleges that Avantor made materially false and misleading statements and failed to disclose adverse facts about its business and competitive positioning [7]. - Specific allegations include that Avantor's competitive position was weaker than represented, and that the company was negatively impacted by increased competition, which contradicted the positive statements made by the defendants [7].